Other Species / Isoforms
  SLP-2 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S17-p
GALLLRGsLLASGRA
Upstream
2 1
Kinase, in vitro:
  • PKCZ (human)
Phosphatases, in vitro:
  • PPP2CA (human)
Putative in vivo kinases:
  • PKCZ (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • anti-CD3/CD28
  • H-89
  • okadaic_acid
  • purvalanol
  • SB202190
  • SL327
  • SP600125
  • staurosporine
  • wortmannin
  • ZM447439
view more >
SLP-2 (human) GALLLRGsLLASGRA S17-p
SLP-2 (mouse) GALLLRGSVQASGRV S17
SLP-2 (rat) GALLLRGSVQASGRI S17
S29-p
GRAPRRAsSGLPRNT
0 4
SLP-2 (human) GRAPRRAsSGLPRNT S29-p
SLP-2 (mouse) GRVPRRAsSGLPRNT S29-p
SLP-2 (rat) GRIPRRASSGLPRNT S29
R74-m1
IPVLDRIrYVQSLKE
0 1
SLP-2 (human) IPVLDRIrYVQSLKE R74-m1
SLP-2 (mouse) IPVLDRIRYVQSLKE R74
SLP-2 (rat) IPVLDRIRYVQSLKE R74
K114-ac
LRIMDPYkASYGVED
0 2
SLP-2 (human) LRIMDPYkASYGVED K114-ac
SLP-2 (mouse) LRIMDPYkASYGVED K114-ac
SLP-2 (rat) LRIMDPYkASYGVED K114-ac
K114-ub
LRIMDPYkASYGVED
0 1
SLP-2 (human) LRIMDPYkASYGVED K114-ub
SLP-2 (mouse) LRIMDPYKASYGVED K114
SLP-2 (rat) LRIMDPYKASYGVED K114
K114
LRIMDPYKASYGVED
0 1
SLP-2 (human) LRIMDPYKASYGVED K114
SLP-2 (mouse) LRIMDPYkASYGVED K114-sc
SLP-2 (rat) LRIMDPYKASYGVED K114
Y124-p
YGVEDPEyAVTQLAQ
0 20
SLP-2 (human) YGVEDPEyAVTQLAQ Y124-p
SLP-2 (mouse) YGVEDPEYAVTQLAQ Y124
SLP-2 (rat) YGVEDPEYAVTQLAQ Y124
K140
TMRSELGKLsLDkVF
0 1
SLP-2 (human) TMRSELGKLsLDkVF K140
SLP-2 (mouse) TMRSELGKLsLDkVF K140
SLP-2 (rat) TMRSELGkLSLDkVF K140-ac
K140-ub
TMRSELGkLsLDkVF
0 3
SLP-2 (human) TMRSELGkLsLDkVF K140-ub
SLP-2 (mouse) TMRSELGKLsLDkVF K140
SLP-2 (rat) TMRSELGKLSLDkVF K140
S142-p
RSELGkLsLDkVFRE
0 1
SLP-2 (human) RSELGkLsLDkVFRE S142-p
SLP-2 (mouse) RSELGKLsLDkVFRE S142-p
SLP-2 (rat) RSELGkLSLDkVFRE S142
K145-ac
LGkLsLDkVFRERES
Upstream
0 14
Treatment
  • MS275
SLP-2 (human) LGkLsLDkVFRERES K145-ac
SLP-2 (mouse) LGKLsLDkVFRERES K145-ac
SLP-2 (rat) LGkLSLDkVFRERES K145-ac
K145-ub
LGkLsLDkVFRERES
0 3
SLP-2 (human) LGkLsLDkVFRERES K145-ub
SLP-2 (mouse) LGKLsLDKVFRERES K145
SLP-2 (rat) LGkLSLDKVFRERES K145
K145-sc
LGkLsLDkVFRERES
0 1
SLP-2 (human) LGkLsLDkVFRERES K145-sc
SLP-2 (mouse) LGKLsLDkVFRERES K145-sc
SLP-2 (rat) LGkLSLDKVFRERES K145
S207-p
KRATVLEsEGTRESA
0 1
SLP-2 (human) KRATVLEsEGTRESA S207-p
SLP-2 (mouse) KRATVLESEGTRESA S207
SLP-2 (rat) KRATVLESEGTRESA S207
K221-ac
AINVAEGkkQAQILA
0 25
SLP-2 (human) AINVAEGkkQAQILA K221-ac
SLP-2 (mouse) AINVAEGkkQAQILA K221-ac
SLP-2 (rat) AINVAEGKKQAQILA K221
K221-sc
AINVAEGkkQAQILA
0 1
SLP-2 (human) AINVAEGkkQAQILA K221-sc
SLP-2 (mouse) AINVAEGkkQAQILA K221-sc
SLP-2 (rat) AINVAEGKKQAQILA K221
K222-ac
INVAEGkkQAQILAs
0 4
SLP-2 (human) INVAEGkkQAQILAs K222-ac
SLP-2 (mouse) INVAEGkkQAQILAS K222-ac
SLP-2 (rat) INVAEGKKQAQILAS K222
S229-p
kQAQILAsEAEkAEQ
0 2
SLP-2 (human) kQAQILAsEAEkAEQ S229-p
SLP-2 (mouse) kQAQILASEAEkAEQ S229
SLP-2 (rat) KQAQILASEAEkAEQ S229
K233-ac
ILAsEAEkAEQINQA
0 7
SLP-2 (human) ILAsEAEkAEQINQA K233-ac
SLP-2 (mouse) ILASEAEkAEQINQA K233-ac
SLP-2 (rat) ILASEAEkAEQINQA K233-ac
K233
ILAsEAEKAEQINQA
0 1
SLP-2 (human) ILAsEAEKAEQINQA K233
SLP-2 (mouse) ILASEAEkAEQINQA K233-sc
SLP-2 (rat) ILASEAEKAEQINQA K233
K250-ub
EASAVLAkAKAKAEA
0 1
SLP-2 (human) EASAVLAkAKAKAEA K250-ub
SLP-2 (mouse) EASAVLAKAKAKAEA K250
SLP-2 (rat) EASAVLAKAKAKAEA K250
S275
HNGDAAASLTVAEQY
0 1
SLP-2 (human) HNGDAAASLTVAEQY S275
SLP-2 (mouse) HNGDAAAsLtVAEQY S275-p
SLP-2 (rat) HNGDAAASLTVAEQY S275
T277
GDAAASLTVAEQYVS
0 1
SLP-2 (human) GDAAASLTVAEQYVS T277
SLP-2 (mouse) GDAAAsLtVAEQYVS T277-p
SLP-2 (rat) GDAAASLTVAEQYVS T277
K288
QYVSAFSKLAKDSNT
0 1
SLP-2 (human) QYVSAFSKLAKDSNT K288
SLP-2 (mouse) QYVSAFSkLAKDsNt K288-ac
SLP-2 (rat) QYVSAFSKLAKDSNT K288
S293
FSKLAKDSNTILLPs
0 1
SLP-2 (human) FSKLAKDSNTILLPs S293
SLP-2 (mouse) FSkLAKDsNtVLLPs S293-p
SLP-2 (rat) FSKLAKDSNTVLLPS S293
T295
KLAKDSNTILLPsNP
0 1
SLP-2 (human) KLAKDSNTILLPsNP T295
SLP-2 (mouse) kLAKDsNtVLLPsNP T295-p
SLP-2 (rat) KLAKDSNTVLLPSNP T295
S300-p
SNTILLPsNPGDVts
0 2
SLP-2 (human) SNTILLPsNPGDVts S300-p
SLP-2 (mouse) sNtVLLPsNPSDVTS S300-p
SLP-2 (rat) SNTVLLPSNPSDVTS S300
T306-p
PsNPGDVtsMVAQAM
0 1
SLP-2 (human) PsNPGDVtsMVAQAM T306-p
SLP-2 (mouse) PsNPSDVTSMVAQAM T306
SLP-2 (rat) PSNPSDVTSMVAQAM T306
S307-p
sNPGDVtsMVAQAMG
0 1
SLP-2 (human) sNPGDVtsMVAQAMG S307-p
SLP-2 (mouse) sNPSDVTSMVAQAMG S307
SLP-2 (rat) SNPSDVTSMVAQAMG S307
T327-p
TKAPVPGtPDsLssG
Upstream
0 32
Treatment
  • EGF
  • LRRK2-IN-1
SLP-2 (human) TKAPVPGtPDsLssG T327-p
SLP-2 (mouse) TKAPVPGAQnSsQsR A327
SLP-2 (rat) TKAPVPGAQNSSEAR A327
D329
APVPGtPDsLssGsS
0 1
SLP-2 (human) APVPGtPDsLssGsS D329
SLP-2 (mouse) APVPGAQnSsQsRRD N329-ng
SLP-2 (rat) APVPGAQNSSEARRD N329
S330-p
PVPGtPDsLssGsSR
0 9
SLP-2 (human) PVPGtPDsLssGsSR S330-p
SLP-2 (mouse) PVPGAQnSsQsRRDV S330
SLP-2 (rat) PVPGAQNSSEARRDV S330
S332-p
PGtPDsLssGsSRDV
0 2
SLP-2 (human) PGtPDsLssGsSRDV S332-p
SLP-2 (mouse) gap -
SLP-2 (rat) gap -
S333-p
GtPDsLssGsSRDVQ
0 2
SLP-2 (human) GtPDsLssGsSRDVQ S333-p
SLP-2 (mouse) VPGAQnSsQsRRDVQ S331-p
SLP-2 (rat) VPGAQNSSEARRDVQ S331
S335-p
PDsLssGsSRDVQGt
0 2
SLP-2 (human) PDsLssGsSRDVQGt S335-p
SLP-2 (mouse) GAQnSsQsRRDVQAT S333-p
SLP-2 (rat) GAQNSSEARRDVQTT A333
T342-p
sSRDVQGtDAsLDEE
0 1
SLP-2 (human) sSRDVQGtDAsLDEE T342-p
SLP-2 (mouse) sRRDVQATDTSIEEL T340
SLP-2 (rat) ARRDVQTTDTSIEEL T340
S345-p
DVQGtDAsLDEELDR
0 3
SLP-2 (human) DVQGtDAsLDEELDR S345-p
SLP-2 (mouse) DVQATDTSIEELGRV S343
SLP-2 (rat) DVQTTDTSIEELGRV S343